FLGT - Fulgent Genetics: Interesting Investment Opportunity

• COVID has fully transformed this business. But investors need to answer what the underlying business, non-COVID revenue, looks like.
• Investors have no visibility into the profit margins of its non-COVID business.
• The stock appears to be cheap, but a lot of question marks remain as to whether it's truly undervalued.
• There's a significant amount of cash rapidly piling up on its balance sheet, expected to reach close to $1 billion by the end of 2021.

For further details see: